Glaukos Corp

Stock Chart, Company Information, and Scan Results

$75.88(as of Oct 21, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Glaukos Corp Company Information, Fundamentals, and Technical Indicators

Stock Price$75.88
Ticker SymbolGKOS
ExchangeNyse
SectorHealthcare
IndustryMedical Devices
Employees995
CountyUSA
Market Cap$4,999.2M
EBIDTA-62.2M
10-Day Moving Average84.72
P/E Ratio-48.75
20-Day Moving Average84.03
Forward P/E Ratio1,666.67
50-Day Moving Average87.40
Earnings per Share-1.61
200-Day Moving Average104.43
Profit Margin-15.84%
RSI39.45
Shares Outstanding57.3M
ATR4.06
52-Week High163.71
Volume3,188,934
52-Week Low77.10
Most Recent Support Level82.19
Book Value765.1M
Most Recent Resistance Level86.74
P/B Ratio5.91
Upper Keltner93.17
P/S Ratio10.45
Lower Keltner74.89
Debt-to-Equity Ratio93.17
Next Earnings Date10/29/2025
Cash Surplus21.7M
Next Ex-Dividend DateUnknown

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Glaukos Corp In Our Stock Scanner

As of Oct 21, 2025
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Undervalued StocksScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: 52-Week LowScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Undervalued Blue ChipsScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.